BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 3237706)

  • 1. A comparison of seven prothrombin time reagents--development of an evaluation strategy.
    Carter CJ; Griswold DJ; Louis RA; Hershler R; Wadsworth LD
    Mod Pathol; 1988 Jul; 1(4):284-7. PubMed ID: 3237706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Quality control of ISI/INR system in oral anticoagulant therapy].
    Kazama M
    Rinsho Ketsueki; 1990 Jun; 31(6):769-75. PubMed ID: 2214167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system.
    Testa S; Morstabilini G; Fattorini A; Galli L; Denti N; D'Angelo A
    Haematologica; 2002 Dec; 87(12):1265-73. PubMed ID: 12495900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results.
    Webster PS; Oleson FB; Paterson DL; Arkin CF; Mangili A; Craven DE; Adcock DM; Lindfield KC; Knapp AG; Martone WJ
    Blood Coagul Fibrinolysis; 2008 Jan; 19(1):32-8. PubMed ID: 18180613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
    Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
    Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of international normalized ratios by a controlled field survey with 4 different thromboplastin reagents.
    Kazama M; Suzuki S; Abe T; Tahara C; Shimazu C; Akiyama Y; Higashi K; Ishiguro I; Kimura T; Motoi S
    Thromb Haemost; 1990 Dec; 64(4):535-41. PubMed ID: 2084938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International standardization of laboratory control of oral anticoagulant therapy: a survey of thromboplastin reagents used for prothrombin time testing.
    van den Besselaar AM
    J Heart Valve Dis; 1993 Jan; 2(1):42-52. PubMed ID: 8269109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prothrombin time and its standardization].
    Kagawa K
    Rinsho Byori; 2002 Aug; 50(8):779-85. PubMed ID: 12373814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Suggestions and propositions to resolve some issues for standardization of prothrombin time and activated partial thromboplastin time].
    Kagawa K; Fukutake K
    Rinsho Byori; 1999 May; 47(5):431-7. PubMed ID: 10375964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
    Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of oral anticoagulant therapy.
    Biemer JJ
    Ann Clin Lab Sci; 1988; 18(6):421-8. PubMed ID: 3239946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of a sensitive rabbit brain thromboplastin and a human placenta thromboplastin for thromboplastin time determination].
    Lämmle B; Furlan M; Sulzer I
    Schweiz Med Wochenschr; 1989 Feb; 119(6):178-83. PubMed ID: 2928740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of three prothrombin time and activated partial thromboplastin time reagent systems on the MLA 700 coagulation analyzer.
    Kritikos VG; Melhem MF
    Clin Lab Sci; 1993; 6(5):302-7. PubMed ID: 10146556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of thromboplastin time with a new standardized thromboplastin from human placenta: results of a cooperative study].
    Barthels M; Bruhn HD; Duckert F; Meyer JG; Dati F; Fuhge P
    J Clin Chem Clin Biochem; 1987 Apr; 25(4):267-80. PubMed ID: 3625130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the quality of prothrombin time technique in the Basque Country].
    Vacas M; Lafuente PJ; Aguirrebeitia MJ; Iriarte JA
    Sangre (Barc); 1998 Feb; 43(1):41-5. PubMed ID: 9577180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant tissue factor as substitute for conventional thromboplastin in the prothrombin time test.
    Tripodi A; Arbini A; Chantarangkul V; Mannucci PM
    Thromb Haemost; 1992 Jan; 67(1):42-5. PubMed ID: 1615481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy.
    Jonsson M; Hillarp A; Svensson P
    Thromb Res; 2004; 114(2):83-9. PubMed ID: 15306149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral anticoagulant monitoring by laboratory or near-patient testing: what a clinician should be aware of.
    Tripodi A; Breukink-Engbers WG; van den Besselaar AM
    Semin Vasc Med; 2003 Aug; 3(3):243-54. PubMed ID: 15199457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Field study of lyophilized calibrant plasmas for fresh plasma INR determination.
    van den Besselaar AM; Houbouyan-Réveillard LL
    Thromb Haemost; 2002 Feb; 87(2):277-81. PubMed ID: 11859852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.